ストックスクリーナーアプリを入手
0.5469
10.42%
-0.0636
前日終値:
$0.6105
開ける：
$0.6006
24時間の取引高:
575.49K
Relative Volume:
0.13
時価総額：
$5.56M
収益：
-
当期純損益:
$-6.64M
株価収益率:
-0.0303
EPS:
-18.0702
ネットキャッシュフロー:
$-5.60M
1週間 パフォーマンス:
-21.42%
1か月 パフォーマンス:
-53.26%
6か月 パフォーマンス:
-98.16%
1年 パフォーマンス:
-98.58%
1日の値動き範囲:
$0.5202
$0.6006
1週間の範囲:
$0.5202
$0.7345
52週間の値動き範囲:
$0.5202
$52.40
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
0.5461 | 6.22M | 0 | -6.64M | -5.60M | -18.07 |
VRTX
Vertex Pharmaceuticals Inc
|
425.82 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.96 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.41 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.50 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clearmind Medicine Inc (CMND) 最新ニュース
Clearmind files European patent for PTSD treatment compounds By Investing.com - Investing.com South Africa
Clearmind files European patent for PTSD treatment compounds - Investing.com UK
Clearmind Medicine Inc. Files European Patent Application for Innovative Psychedelic Compounds Targeting PTSD Treatment - Quiver Quantitative
Clearmind (Nasdaq: CMND) files European patent for PTSD psychedelics - Stock Titan
Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd - TradingView
Clearmind seeks European patent for psychedelic PTSD compounds - Stock Titan
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic ... - Caledonian Record
Clearmind Medicine Announces Filing of European Patent Application for Novel Psychedelic Compounds for the Treatment of PTSD - marketscreener.com
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Clearmind Medicine (NASDAQ: CMND) registers 22.6M resale shares tied to $10M notes - Stock Titan
Clearmind Medicine amends securities agreement and announces board changes - Investing.com
Leadership shifts at Clearmind Medicine (NASDAQ: CMND) as chair exits - Stock Titan
Clearmind shares surge as CMND-100 achieves primary endpoint in clinical trial - MSN
Clearmind Announces Changes To Senior Management As It Accelerates Development Of Its IP Portfolio - TMX Newsfile
Clearmind Medicine regains compliance with Nasdaq - MSN
Clearmind Medicine to enact 1-for-40 reverse share split; shares down - MSN
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation - The Manila Times
Clearmind Medicine Inc. Pursues Breakthrough Therapy Designation for Alcohol Use Disorder Treatment CMND-100 Following Positive Clinical Trial Results - Quiver Quantitative
Clearmind (NASDAQ: CMND) explores FDA breakthrough path for CMND-100 in AUD - Stock Titan
Alcohol disorder treatment from Clearmind eyes FDA breakthrough path - Stock Titan
CMND stock set for biggest intraday gains in over three years — here’s why retail is eyeing further upside - MSN
Clearmind Medicine Inc. (CMND) Stock Price Today - MEXC Exchange
CMND Technical Analysis | Trend, Signals & Chart Patterns | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Why is Clearmind Medicine stock sliding on Wednesday? - MSN
Why Is Clearmind Medicine Stock Sliding On Wednesday? - Benzinga
Crude Oil Surges Over 6%; Investar Holding Shares Gain Following Q1 Earnings - Sahm
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results - Sahm
Clearmind Medicine (NASDAQ: CMND) adds $2.7M notes and converts $2.68M to shares - Stock Titan
Dow Gains Over 200 Points; US Retail Sales Top Estimates - Sahm
Clearmind’s CMND-100 meets primary endpoint in phase I/IIa trial - Investing.com India
Clearmind Medicine (CMND) issues $2.7M in new convertible promissory notes at 90% of principal - Stock Titan
Clearmind Medicine (CMND) Stock Surges 100% After Drug Trial Hit Safety Goals - MEXC Exchange
Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care - The Manila Times
[6-K] Clearmind Medicine Inc. Current Report (Foreign Issuer) | CMND SEC FilingForm 6-K - Stock Titan
Trump order spotlights psychedelic drugs for veterans, Clearmind says - Stock Titan
Clearmind’s CMND-100 meets primary endpoint in phase I/IIa trial By Investing.com - Investing.com South Africa
CMND Stock Jumps As Psychedelic Tailwinds Lift Clearmind - StocksToTrade
Clearmind Medicine jumps 64.7% after CMND-100 hits key safety endpoint in early AUD study - Quiver Quantitative
Clearmind Medicine's CMND-100 Achieves Key Safety Milestone in Alcohol Use Disorder Trial: What U.S. - AD HOC NEWS
Clearmind Medicine Says Drug Candidate Met Primary Endpoint in Phase I/IIa Trial to Treat Alcohol Use Disorder - Moomoo
Clearmind Medicine (CMND) Stock Doubles as CMND-100 Passes Critical Safety Milestone - Blockonomi
Why Is Clearmind Stock Rising Monday?Clearmind Medicine (NASDAQ:CMND) - Benzinga
Clearmind Medicine CMND Stock Jumps On Psychedelic Policy Tailwinds - timothysykes.com
Clearmind Medicine Inc (CMND) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):